Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 3,608,809 shares, a decrease of 1.4% from the February 28th total of 3,659,572 shares. Based on an average trading volume of 130,210 shares, the days-to-cover ratio is currently 27.7 days.
In other news, CEO Gregory T. Went sold 2,807 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $17.03, for a total value of $47,803.21. Following the transaction, the chief executive officer now owns 166,526 shares of the company’s stock, valued at $2,835,937.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders sold 4,256 shares of company stock worth $72,480. 31.79% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of Adamas Pharmaceuticals by 4.9% in the third quarter. JPMorgan Chase & Co. now owns 163,450 shares of the specialty pharmaceutical company’s stock valued at $2,683,000 after buying an additional 7,651 shares in the last quarter. Sio Capital Management LLC increased its position in shares of Adamas Pharmaceuticals by 17.0% in the third quarter. Sio Capital Management LLC now owns 66,110 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after buying an additional 9,610 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of Adamas Pharmaceuticals by 2.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 571,789 shares of the specialty pharmaceutical company’s stock valued at $9,383,000 after buying an additional 11,910 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Adamas Pharmaceuticals during the third quarter valued at approximately $219,000. Finally, Opus Point Partners Management LLC boosted its stake in Adamas Pharmaceuticals by 32.7% in the third quarter. Opus Point Partners Management LLC now owns 60,000 shares of the specialty pharmaceutical company’s stock valued at $985,000 after buying an additional 14,802 shares during the last quarter. Hedge funds and other institutional investors own 75.44% of the company’s stock.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 0.13% during midday trading on Thursday, reaching $15.65. The company’s stock had a trading volume of 85,509 shares. The company’s market capitalization is $347.73 million. The stock’s 50-day moving average is $17.08 and its 200-day moving average is $16.26. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $19.50.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 38.31% and a negative net margin of 5,267.99%. The firm earned $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. During the same period in the previous year, the firm posted ($0.58) EPS. The company’s quarterly revenue was down 92.6% compared to the same quarter last year. On average, equities analysts expect that Adamas Pharmaceuticals will post ($3.26) earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Mizuho reiterated a “buy” rating and set a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Thursday, January 5th. Zacks Investment Research cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 16th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Adamas Pharmaceuticals has an average rating of “Buy” and a consensus price target of $28.33.
WARNING: “Adamas Pharmaceuticals Inc (ADMS) Sees Significant Decrease in Short Interest” was posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2017/04/20/adamas-pharmaceuticals-inc-adms-short-interest-update-updated.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.